Popular on eTradeWire
- San Jose Holiday Lights Returns to Downtown San Jose for the 2026 Season - 6411
- San Jose Holiday Lights: Group Ticket Discounts for Companies, Schools, Organizations - 2109
- Pleasanton Welcomes The Great Junk Hunt – Discover Unique Vintage Treasures and Holiday Finds! - 1402
- Eight Teams Set to Compete in the 2026 MDF Hoop House Tip-Off Classic at Tarrant High School - 622
- Dryer Vent Cleaning New Jersey: Freehold Families Urged to Check Airflow as Laundry Season Begins - 432
- Fivio Foreign Set to Drop on Friday Kingdom Music Single Release "You Make Me" single - 395
- Reggae on the River Returns to County Line June 25 - 27, 2027 - 337
- Okaloosa Recovery Centers Combine Oct. 26: What Niceville, Shalimar and FWB Homeowners Should Know - 279
- Celebrate more, Remember forever - 269
- Red Carpet, Star Power and Comedy Come to Cranford for "Midlife Women: It's Your Opening Night!" - 245
BREAKTHROUGH TROP2 Research Reveals New REQORSA® Opportunities as Roche Collaboration Strengthens Precision Lung Cancer Strategy
eTradeWire News/10853469
New Preclinical Findings Show TROP2 Levels May Help Predict REQORSA Treatment Response—and That Modifying TROP2 Expression May Increase Cancer Cell Sensitivity to Gene Therapy. Combined With the Roche Diagnostics Collaboration, Expanding TUSC2 Research and Advancing Clinical Programs, Genprex, Inc. (NAS DAQ: GNPX) Is Building Significant Momentum Across Its Innovative Biotechnology Platform.
AUSTIN, Texas - eTradeWire -- Genprex, Inc. (N A S D A Q: GNPX) $GNPX is bringing another exciting development to its growing gene therapy story with today's November 19 announcement of new preclinical data identifying TROP2 as a potential predictive biomarker for its lead investigational therapy, REQORSA® (quaratusugene ozeplasmid). Presented at the 2026 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, the research offers important new insights into how TROP2 expression may influence the response of non-small cell lung cancer (NSCLC) to REQORSA.
What makes today's announcement especially interesting is that researchers are investigating more than simply whether TROP2 can identify patients likely to respond. The new findings also suggest that changing TROP2 expression may influence how cancer cells respond to TUSC2 gene therapy, potentially opening another avenue for improving treatment sensitivity.
For Genprex investors, this represents an important addition to an increasingly sophisticated precision-oncology strategy. The company is working to combine its innovative gene therapy platform with biomarker research that could help researchers better understand treatment response and identify patients who may benefit most.
Today's Big News: TROP2 Research Reveals Another Potential Advantage for REQORSA
The November 19 announcement highlights findings from research titled "TROP2 Predicts Response to TUSC2 Gene Therapy and Its Modulation Sensitizes Non-Small Cell Lung Cancer to Treatment."
Researchers evaluated multiple NSCLC cell lines and patient-derived organoid models to investigate the relationship between TROP2 expression and response to TUSC2 gene delivery.
The findings were particularly noteworthy:
Perhaps the most intriguing aspect involved experiments examining whether changing TROP2 expression could influence treatment sensitivity.
Researchers introduced TROP2 into TROP2-low NSCLC cancer cells, including H460 and H1299 models. This significantly increased TUSC2-induced apoptosis, bringing the response to levels similar to cells naturally expressing higher TROP2.
More on eTradeWire News
This is an important scientific observation because it suggests TROP2 may have a role beyond simply identifying tumors that respond differently. Modifying its expression could potentially become another research strategy for enhancing REQORSA treatment.
The company believes these findings could help inform future patient-selection strategies and additional research into improving treatment response.
Roche Diagnostics Collaboration: A Powerful Addition to Genprex's Strategy
One of Genprex's most important strategic developments remains its collaboration with Roche Diagnostics, announced August 3.
The collaboration focuses on validating biomarker assays for non-small cell lung cancer, with particular attention to TROP2 and PTEN.
Roche brings extensive diagnostic expertise to the relationship, while Genprex contributes its developing REQORSA gene therapy platform and growing body of clinical and preclinical research.
The objective is to develop a more refined approach to identifying patients who may be more likely to benefit from REQORSA.
Previous clinical research suggested that higher TROP2 expression and lower PTEN expression were associated with longer progression-free survival in certain NSCLC patient groups.
Today's new findings add another important scientific component to this collaboration by providing additional evidence supporting the investigation of TROP2 as a potential predictive biomarker.
Genprex anticipated completing the Roche-related assay validation studies around the end of 2026, with potential incorporation into its NSCLC clinical program following successful validation.
The combination of Roche's diagnostic capabilities and Genprex's gene therapy research could become an important part of the company's precision-medicine strategy.
REQORSA: Advancing an Innovative Approach to Lung Cancer
At the center of Genprex's oncology platform is REQORSA, also known as quaratusugene ozeplasmid.
The investigational therapy is designed to deliver the TUSC2 tumor-suppressor gene into cancer cells using Genprex's proprietary ONCOPREX Delivery System, which utilizes lipid-based nanoparticles.
TUSC2 expression is reduced or absent in more than 80% of NSCLC cases and nearly all small cell lung cancers, making it an important target for investigation.
REQORSA is designed to restore tumor-suppressor activity and influence multiple biological pathways involved in cancer progression, including MAPK and mTOR signaling, cell-cycle regulation and programmed cancer-cell death.
Genprex is advancing two important clinical initiatives:
Acclaim-1: Evaluating REQORSA in combination with AstraZeneca's Tagrisso in patients with advanced NSCLC carrying specific EGFR mutations.
Acclaim-3: Evaluating REQORSA in an extensive-stage small cell lung cancer treatment strategy.
Both programs have received FDA Fast Track designation, while the small cell lung cancer program has also received Orphan Drug Designation.
New TUSC2 Research Expands the Scientific Story
Genprex has also been generating interest through its sponsored research collaboration with Meharry Medical College.
More on eTradeWire News
Recent research has examined TUSC2's role in cellular resilience, mitochondrial function and biological processes associated with aging.
On November 5, the company highlighted patient-derived research involving blood samples from 11 lung cancer patients receiving REQORSA. Researchers identified changes in gene-expression patterns associated with mitochondrial adaptation, autophagy, cellular maintenance and protein quality control.
These findings add another dimension to the understanding of TUSC2's biological activity in humans and complement the company's broader scientific investigation.
Diabetes Gene Therapy Adds Another Development Opportunity
Beyond oncology, Genprex is pursuing an additional opportunity through its diabetes gene therapy program.
The approach uses AAV technology to deliver Pdx1 and MafA genes to the pancreas, with the objective of restoring insulin-producing cell function.
Preclinical studies have produced encouraging findings in Type 1 and Type 2 diabetes models, including improvements in glucose control and insulin-related measures.
In August, Genprex announced the selection of a U.S.-based contract development and manufacturing organization to begin manufacturing scale-up for its diabetes gene therapy candidate.
This provides another important development program as the company works toward future clinical research.
The Road Ahead: Important Catalysts for GNPX Investors
Genprex has several important developments to watch as 2026 progresses:
Genprex Is Building an Intriguing Precision Gene Therapy Platform
Today's November 19 announcement adds another important milestone to Genprex's developing story. The TROP2 findings are particularly interesting because they suggest two potential opportunities: identifying patients more likely to respond to REQORSA and investigating whether changing TROP2 expression could increase treatment sensitivity.
Combined with the Roche Diagnostics collaboration, these findings strengthen the scientific foundation behind Genprex's precision-oncology ambitions.
The company's continued TUSC2 research, advancing lung cancer clinical programs and separate diabetes gene therapy initiative provide multiple areas of development to follow.
For investors watching emerging biotechnology opportunities, Genprex is building an increasingly compelling story around innovative gene therapy, strategic diagnostic collaboration and personalized cancer treatment. With today's new TROP2 findings adding another exciting dimension to REQORSA, GNPX has important scientific milestones ahead as it works to translate its research into meaningful clinical progress.
For more information on $GNPX visit: www.genprex.com and https://compasslivemedia.com/gnpx/
Media Contact:
Company Name: Genprex, Inc.
Contact: Kalyn Dabbs
Email: media@genprex.com
Phone: (877) 774-GNPX (4679)
Country: United States
Website: www.genprex.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
What makes today's announcement especially interesting is that researchers are investigating more than simply whether TROP2 can identify patients likely to respond. The new findings also suggest that changing TROP2 expression may influence how cancer cells respond to TUSC2 gene therapy, potentially opening another avenue for improving treatment sensitivity.
For Genprex investors, this represents an important addition to an increasingly sophisticated precision-oncology strategy. The company is working to combine its innovative gene therapy platform with biomarker research that could help researchers better understand treatment response and identify patients who may benefit most.
Today's Big News: TROP2 Research Reveals Another Potential Advantage for REQORSA
The November 19 announcement highlights findings from research titled "TROP2 Predicts Response to TUSC2 Gene Therapy and Its Modulation Sensitizes Non-Small Cell Lung Cancer to Treatment."
Researchers evaluated multiple NSCLC cell lines and patient-derived organoid models to investigate the relationship between TROP2 expression and response to TUSC2 gene delivery.
The findings were particularly noteworthy:
- Approximately 50% of the 10 NSCLC cell lines evaluated demonstrated primary resistance to TUSC2 gene delivery.
- Approximately 50% of the 12 patient-derived organoid models also demonstrated primary resistance.
- Low TROP2 protein expression was consistently associated with primary resistance across multiple preclinical models.
- Analysis of pretreatment tumor biopsies from patients enrolled in a TUSC2 gene therapy clinical trial provided additional supporting evidence.
Perhaps the most intriguing aspect involved experiments examining whether changing TROP2 expression could influence treatment sensitivity.
Researchers introduced TROP2 into TROP2-low NSCLC cancer cells, including H460 and H1299 models. This significantly increased TUSC2-induced apoptosis, bringing the response to levels similar to cells naturally expressing higher TROP2.
More on eTradeWire News
- Author Féline na Coille Releases New Dystopian Supernatural Thriller Let There Be Light
- ECO Fuel Systems Offers Diesel Truck Fleets Fuel Savings and Reduced Emissions
- Casting Not Hiring: How Secrets from Great Theater Are Shaping the Way We Do Business
- Cards Cash Rewards Launches Featured Products Initiative
- SEC-INT Announces the Launch of Its First Three-Book Collection Exploring Counterintelligence
This is an important scientific observation because it suggests TROP2 may have a role beyond simply identifying tumors that respond differently. Modifying its expression could potentially become another research strategy for enhancing REQORSA treatment.
The company believes these findings could help inform future patient-selection strategies and additional research into improving treatment response.
Roche Diagnostics Collaboration: A Powerful Addition to Genprex's Strategy
One of Genprex's most important strategic developments remains its collaboration with Roche Diagnostics, announced August 3.
The collaboration focuses on validating biomarker assays for non-small cell lung cancer, with particular attention to TROP2 and PTEN.
Roche brings extensive diagnostic expertise to the relationship, while Genprex contributes its developing REQORSA gene therapy platform and growing body of clinical and preclinical research.
The objective is to develop a more refined approach to identifying patients who may be more likely to benefit from REQORSA.
Previous clinical research suggested that higher TROP2 expression and lower PTEN expression were associated with longer progression-free survival in certain NSCLC patient groups.
Today's new findings add another important scientific component to this collaboration by providing additional evidence supporting the investigation of TROP2 as a potential predictive biomarker.
Genprex anticipated completing the Roche-related assay validation studies around the end of 2026, with potential incorporation into its NSCLC clinical program following successful validation.
The combination of Roche's diagnostic capabilities and Genprex's gene therapy research could become an important part of the company's precision-medicine strategy.
REQORSA: Advancing an Innovative Approach to Lung Cancer
At the center of Genprex's oncology platform is REQORSA, also known as quaratusugene ozeplasmid.
The investigational therapy is designed to deliver the TUSC2 tumor-suppressor gene into cancer cells using Genprex's proprietary ONCOPREX Delivery System, which utilizes lipid-based nanoparticles.
TUSC2 expression is reduced or absent in more than 80% of NSCLC cases and nearly all small cell lung cancers, making it an important target for investigation.
REQORSA is designed to restore tumor-suppressor activity and influence multiple biological pathways involved in cancer progression, including MAPK and mTOR signaling, cell-cycle regulation and programmed cancer-cell death.
Genprex is advancing two important clinical initiatives:
Acclaim-1: Evaluating REQORSA in combination with AstraZeneca's Tagrisso in patients with advanced NSCLC carrying specific EGFR mutations.
Acclaim-3: Evaluating REQORSA in an extensive-stage small cell lung cancer treatment strategy.
Both programs have received FDA Fast Track designation, while the small cell lung cancer program has also received Orphan Drug Designation.
New TUSC2 Research Expands the Scientific Story
Genprex has also been generating interest through its sponsored research collaboration with Meharry Medical College.
More on eTradeWire News
- Woodward Sports Network Welcomes Detroit Radio Legend Dr. Darrius for New Show With Braylon Edwards
- Scott Glickson Joins STS Capital Partners as Managing Director
- Top National 40 Under 40 Torchbearer Andy Yau, REALTOR®, Lists in Sanford as New Listings Fall
- Izzies Bikinies Teases Black Friday Discount on Its Custom Builder Bikinis
- Victorian Homeowners Encouraged to Understand Heat Pump Rebates Before Choosing an Upgrade
Recent research has examined TUSC2's role in cellular resilience, mitochondrial function and biological processes associated with aging.
On November 5, the company highlighted patient-derived research involving blood samples from 11 lung cancer patients receiving REQORSA. Researchers identified changes in gene-expression patterns associated with mitochondrial adaptation, autophagy, cellular maintenance and protein quality control.
These findings add another dimension to the understanding of TUSC2's biological activity in humans and complement the company's broader scientific investigation.
Diabetes Gene Therapy Adds Another Development Opportunity
Beyond oncology, Genprex is pursuing an additional opportunity through its diabetes gene therapy program.
The approach uses AAV technology to deliver Pdx1 and MafA genes to the pancreas, with the objective of restoring insulin-producing cell function.
Preclinical studies have produced encouraging findings in Type 1 and Type 2 diabetes models, including improvements in glucose control and insulin-related measures.
In August, Genprex announced the selection of a U.S.-based contract development and manufacturing organization to begin manufacturing scale-up for its diabetes gene therapy candidate.
This provides another important development program as the company works toward future clinical research.
The Road Ahead: Important Catalysts for GNPX Investors
Genprex has several important developments to watch as 2026 progresses:
- Continued investigation of TROP2 as a potential predictive biomarker for REQORSA.
- Further research into whether TROP2 modulation can enhance treatment sensitivity.
- Anticipated completion of Roche Diagnostics biomarker assay validation.
- Continued advancement of the Acclaim-1 and Acclaim-3 clinical programs.
- Additional TUSC2 research and diabetes gene therapy development.
Genprex Is Building an Intriguing Precision Gene Therapy Platform
Today's November 19 announcement adds another important milestone to Genprex's developing story. The TROP2 findings are particularly interesting because they suggest two potential opportunities: identifying patients more likely to respond to REQORSA and investigating whether changing TROP2 expression could increase treatment sensitivity.
Combined with the Roche Diagnostics collaboration, these findings strengthen the scientific foundation behind Genprex's precision-oncology ambitions.
The company's continued TUSC2 research, advancing lung cancer clinical programs and separate diabetes gene therapy initiative provide multiple areas of development to follow.
For investors watching emerging biotechnology opportunities, Genprex is building an increasingly compelling story around innovative gene therapy, strategic diagnostic collaboration and personalized cancer treatment. With today's new TROP2 findings adding another exciting dimension to REQORSA, GNPX has important scientific milestones ahead as it works to translate its research into meaningful clinical progress.
For more information on $GNPX visit: www.genprex.com and https://compasslivemedia.com/gnpx/
Media Contact:
Company Name: Genprex, Inc.
Contact: Kalyn Dabbs
Email: media@genprex.com
Phone: (877) 774-GNPX (4679)
Country: United States
Website: www.genprex.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Source: CorporateAds
0 Comments
Latest on eTradeWire News
- Greater Atlanta Home Builders Association Honors David Weekley Homes with Eight Obie Awards
- Image to Layers Launches AI Character-to-Layers Engine for Fast 2D Rigging Prep
- Drifter Merch Named Authorized Retailer of Widespread Panic Official Merchandise
- Orchid Island Brewery Expands Highlighting Florida Indian River Citrus with Grove to Glass Beers
- Lish Digital Launches Digital Growth Framework for Measurable Business Results
- Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Dallas–Fort Worth
- CARBONELL AWARDS Announce Winners for 2025-2026 Theater Season
- Continuous Process Solutions expands wood-based panel offering with new press consumables range
- Virens Named Most Trusted Small Business Digital Marketing Agency in South East England
- Southern Pool Designs Wins 2026 PHTA International Gold Award and Luxury Pools Pinnacle Award
- CIMdata Announces Dates and Global Locations for the 2027 PLM Market & Industry Forum Series
- Custom vests before Black Friday: Arklavo shares 2 to 4 day production timing for embroidered teams
- Pony 4 Precious Brings More Books to Yavapai County Children
- It's Not Property — It's Money: Texas Lone Star Recovery Group Explains Unclaimed Property
- Aussie Energreen Publishes Guide to Choosing a 20kWh Solar Battery for Perth Homes
- Andre The Beast Crayton Releases "Global Game" — An Independently Owned Anthem With A Music Video
- KKM Launches Curated Online Shop
- SEM Link Launches "Cultivating STEM Scholars through Reading" Book Drive
- Weinberg Center to hold centennial celebration on exact date the theater opened 100 years ago
- Attend GoldenFest and Pet Fest and learn more about pet waste impacts on environment



